Glycopyrrolate and Post-Operative Urinary Retention: A Narrative Review

Jason Low 1, Mauricio Escobar 2, Sebastian Baquero 2, Howard S. Goldman 2, Gerald Rosen 2

1. Anesthesiology, Herbert Wertheim College of Medicine of Florida International University, Miami, USA
2. Anesthesiology, Mount Sinai Medical Center of Florida, Miami Beach, USA

Corresponding author: Jason Low, jlow004@fiu.edu

Abstract

The use of non-depolarizing neuromuscular blockade (NDNMB) necessitates the use of reversal agents. Glycopyrrolate, an anticholinergic agent, is commonly used in combination with neostigmine, an anticholinesterase, for the reversal of neuromuscular blockade medications. Glycopyrrolate is known to effect on the genitourinary system adversely with an inhibitory effect on bladder contraction, bladder hypotonia, and increase in the frequency of urinary retention. Many studies analyzing the association between glycopyrrolate and urinary retention are outdated and published over a decade ago. The decade old studies were retrospective and did not consider post-operative urinary retention (POUR) as a primary outcome. The purpose of this manuscript is to review the association between glycopyrrolate administration and post-operative urinary retention in the perioperative setting.

Introduction And Background

Postoperative urinary retention (POUR) is defined as the inability to initiate micturition in the presence of a full bladder during the early post-operative period [1]. The reported incidence of POUR in the literature ranges from 2-50% [1]. POUR has been a drawback related to surgical procedures necessitating non-depolarizing neuromuscular blockade (NDNMB) and remains a barrier to providing same day surgical care [2]. The administration of glycopyrrolate in general anesthesia significantly increases the risk of post-operative urinary retention, thus placing an emotional tax on patients as well as an economic burden to the healthcare system.

Review

Risk Factors for POUR

A meta-analysis conducted by Mason et al. established several risk factors for post-operative urinary retention in patients undergoing ambulatory surgery [3]. Increased age was shown to be associated with POUR (odds ratio of 2.11, 95% confidence interval (CI) 1.15-3.86) in patients older than 60 years old [3]. The presence of lower urinary tract symptoms, such as frequency, urgency, straining, and weak stream, significantly increased the risk of POUR (odds ratio of 2.83, CI 1.57-5.08) (table 1) [3]. Sex was not associated with developing urinary retention post-operatively, although it is generally understood that male sex is a risk factor for non-operative urinary retention due to prostatic hypertrophy [3]. The usage of a preoperative alpha-blocker to treat prostatic hypertrophy significantly decreases the incidence of POUR (odds ratio of 0.37, CI 0.15-0.91) [3].

How to cite this article

Low J, Escobar M, Baquero S, et al. (November 08, 2020) Glycopyrrolate and Post-Operative Urinary Retention: A Narrative Review. Cureus 12(11): e11379. DOI 10.7759/cureus.11379
| Table 1. Risk Factors for POUR |
|--------------------------------|
| Age >60 [3]                   |
| IV administration [1]         |
| Previous Lower Urinary Tract Symptoms [3] |
| Frequency                     |
| Urgency                       |
| Straining                     |
| Weak Stream                   |
| Medications                   |
| Anticholinergics (atropine, glycopyrrolate) [4-6] |
| Beta-blockers [4]             |
| Sympathomimetcs [4,5]         |

**TABLE 1: Risk Factors for POUR**

POUR: post-operative urinary retention

Specific surgical procedures affect the incidence of post-operative urinary retention more than others, with the greatest incidence occurring in patients undergoing joint arthroplasty [1]. The incidence of acute POUR following total joint arthroplasty ranges from 0% to 75%, compared to 1-52% for anorectal surgery, and 5.9-38% for hernia repair [1] (Table 2). Patients with comorbidities such as neurologic diseases (stroke, multiple sclerosis, poliomyelitis, spinal lesions, cerebral palsy, and diabetic and alcoholic neuropathy) are at a greater risk for developing urinary retention (Table 3) [4,7]. Medications such as anticholinergics, β-blockers, and sympathomimetcs increase the risk of urinary retention [4-6]. Intravenous administration of more than 730 ml of fluids during the perioperative period also increased the risk of POUR by 2.3 times in patients undergoing hernia repair and anorectal surgery, compared to other surgeries [1].

| Table 2. Surgical Risk Factors for POUR [1] |
|--------------------------------------------|
| Joint arthroplasty                         |
| Anorectal surgery                          |
| Hernia repair                              |
| Previous pelvic surgery                    |

**TABLE 2: Surgical Risk Factors for POUR**

POUR: post-operative urinary retention
Table 3. Comorbid Conditions for POUR [4,7]

| Condition          |
|--------------------|
| Stroke             |
| Poliomyelitis      |
| Cerebral Palsy     |
| Multiple Sclerosis |
| Spinal Lesions     |
| Diabetic Neuropathy|
| Alcoholic Neuropathy|

| TABLE 3: Comorbid Conditions for POUR |
|--------------------------------------|
| POUR: post-operative urinary retention |

**Glycopyrrolate**

Anticholinergics are used in general anesthesia to prevent the muscarinic effect of anticholinesterases, i.e. bradycardia. Glycopyrrolate, an anticholinergic agent, is commonly used in conjunction with neostigmine, an anticholinesterase, for the reversal of neuromuscular blockade created by NDNMB. Bladder detrusor contraction and internal urethral sphincter relaxation during micturition are controlled by parasympathetic stimulation via muscarinic receptors; therefore, blockade of these post-junctional excitatory muscarinic receptors in the detrusor muscle causes bladder hypotonia and increases the frequency of urinary retention [8]. Besides reversing neuromuscular blockade, glycopyrrolate is also used to decrease oral, tracheobronchial, and pharyngeal secretions, and to treat bradycardia [9].

In one of the few available contemporary prospective studies regarding the use of glycopyrrolate, Scott et al. found that glycopyrrolate administration was independently associated with POUR (OR 3.48, CI 1.08–11.24 p = 0.0370) [6]. This study, however, was limited by incomplete data, a low number of patients with both POUR and glycopyrrolate administration, and a low incidence of other risk factors [6]. Additional prospective studies consisting of a larger patient sample should be conducted to obtain a more accurate estimation of the sample population and improve statistical models.

**Physical and Psychological Impact**

POUR negatively impacts the patient both physically and psychologically. The sense of urinary urgency begins when bladder volume reaches 300 mL [1]. An overextended bladder is extremely painful and can cause vomiting, arrhythmias, hypotension or hypertension in some patients [10]. Acute urinary retention may lead to bladder tissue damage and urinary tract infection, impairing renal glomerular and tubular function [11]. POUR is usually managed with urinary catheterization which not only is uncomfortable for the patient, but increases both the risk of bleeding due to trauma in the urogenital tract and urinary tract infections [12]. Patients with catheters in situ that are managed in an outpatient setting are at a 5% per day risk of developing a urinary tract infection, with 2–4% of those further progressing to bacteremia [13,14]. Psychologically, patients may also experience great distress due to an unexpected surgical complication as well as embarrassment, vulnerability, and shame of urinary catheterization in non-private settings [15].

**Economic Impact**

Direct economic impacts from POUR are transferred to the healthcare system. Approximately 28.6 million ambulatory surgery visits were made in the United States in 2010 [16]. Considering that 33% of all procedures were performed on patients aged 65 and over, POUR is a significant barrier to early or same-day discharge in this population [16,17]. It is believed to increase the discharge time in 19% of outpatients [18,19] and is responsible for 20–25% of unplanned inpatient admissions following day-case surgery [20,21]. These unplanned readmissions have direct cost implications for the healthcare organization. Overnight admissions decrease the availability of beds for emergency and elective admissions and results in the loss of 11–70% of the cost savings expected from ambulatory surgery [22]. Some patients may be required to leave the hospital with an indwelling catheter, while also requiring ongoing outpatient management in urology and specialty clinics.

**Future Directions**

Fortunately, options besides glycopyrrolate exist for reversing NDNMB paralysis so that POUR can be avoided in high-risk patients. Specifically, Sugammadex, a selective relaxant binding agent, is a viable
alternative that has recently been introduced into clinical practice [5]. Sugammadex is used to reverse muscle relaxation through strong, rapid, one-to-one, encapsulation with NDNMB in the plasma [6,8]. It has no effect on acetylcholinesterase and prevents blockade of the neuromuscular junction without the undesired muscarinic side effects [22, 23]. Although the direct cost of Sugammadex may be more expensive than glycopyrrolate, it indirectly may be more cost-effective in the long-run due to the amount of time saved by rapid reversal of paralysis as well as reducing incidence of POUR [23].

Cha et al. compared the incidence of urinary retention between patients who received Sugammadex and those who received anticholinesterases with anticholinergics for reversal of neuromuscular blockade in a retrospective cohort. They found that the incidence of urinary retention was significantly lower in the Sugammadex group compared to the glycopyrrolate group (36.1 vs. 48.8%, P = 0.005) [8]. They concluded that the use of Sugammadex was associated with a lower incidence of urinary retention by avoiding glycopyrrolate. Their sample, however, was limited to subjects who underwent total knee arthroplasty, which limited generalizability of their findings. Further prospective studies should be conducted to investigate the role of Sugammadex in reducing the incidence of urinary retention compared to glycopyrrolate administration.

Conclusions
The number of ambulatory surgical procedures is increasing especially among the elderly population and POUR is one of the most common causes of unplanned hospital admissions after surgery in this patient population. It is, therefore, critical to quantify the incidence of urinary retention and to understand risk factors. This information can be used to optimize operative planning and to help provide better counsel for high-risk patients. Initiating prophylactic interventions such as administration of alpha blockers, magnesium (reduces bladder spasm), and reduction of opioids may decrease the incidence of POUR and should be considered. However, additional randomized controlled trials are necessary to determine the effectiveness of these interventions in the setting of glycopyrrolate administration.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Baldini G, Bagry H, Apriglian A, Carli F: Postoperative urinary retention: anesthetic and perioperative considerations. Anesthesiology, 2009, 110:1139–1157. 10.1097/ALN.0b013e318197aeca
2. Salvati EP, Kleckner MS: Urinary retention in anorectal and colonic surgery. Am J Surg. 1957, 94:114–117. 10.1016/0002-9610(57)90629-3
3. Mason SE, Scott AJ, Mayer E, Purkayastha S: Patient-related risk factors for urinary retention following ambulatory general surgery: a systematic review and meta-analysis. Am J Surg. 2016, 211:1126–1154. 10.1016/j.amjsurg.2015.04.021
4. Tammela T, Kontturi M, Lukkarinen O: Postoperative urinary retention. I. Incidence and predisposing factors. Scand J Urol Nephrol. 1986, 20:197–201. 10.3109/000365598609022449
5. Peters G, Rimm EB, Robillard RJ, Argy O: Factors influencing postoperative urinary retention in patients undergoing elective inguinal hernioplasty. Am J Surg. 1991, 161:431–433. 10.1016/0002-9610(91)91105-R
6. Scott AJ, Mason SE, Langdon AJ, et al.: Prospective risk factor analysis for the development of postoperative urinary retention following ambulatory general surgery. World J Surg. 2018, 42:5874–5879. 10.1007/s00268-018-4697-4
7. Toyonaga T, Matsushima M, Sogawa N, et al.: Postoperative urinary retention after surgery for benign anorectal disease: potential risk factors and strategy for prevention. Int J Colorectal Dis. 2006, 21:676–682. 10.1007/s00384-005-0077-2
8. Cha J-E, Park SW, Choi Yi, et al.: Sugammadex use can decrease the incidence of post-operative urinary retention by avoiding anticholinergics: a retrospective study. Anesth Pain Med. 2018, 18:40–46. 10.17085/apm.2018.18.1.40
9. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M: Treatment of sialorrhea With glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med. 2000, 154:1214–1218. 10.1001/archpedi.154.12.1214
10. Kamphuis ET, Ionescu Tl, Kuipers PW, de Gier J, van Venrooij GE, Boon TA: Recovery of storage and emptying functions of the urinary bladder after spinal anesthesia with lidocaine and with bupivacaine in men. Anesthesiology. 1998, 88:310–316. 10.1097/00000542-199802000-00007
11. Mustonen S, Ala-Houhala I, Tammela TL: Proteinuria and renal function during and after acute urinary retention. J Urol. 1999, 161:1781–1784. 10.1016/S0022-5347(05)68798-8
12. Igawa Y, Wyndaele J-I, Nishizawa O: Catheterization: possible complications and their prevention and treatment. Int J Urol. 2008, 15:481–485. 10.1111/j.1442-242X.2008.02075.x
13. Maki DG, Tambyah PA: Engineering out the risk for infection with urinary catheters. Emerg Infect Dis. 2001,
14. Stamm WE: Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med. 1991, 91:65-71. 10.1016/0002-9343(91)90345-X

15. Wilde MH: Life with an indwelling urinary catheter: the dialectic of stigma and acceptance. Qual Health Res. 2003, 13:1189-1204. 10.1177/1049732303257115

16. Hall MJ, Schwartzman A, Zhang J, Liu X: Ambulatory surgery data from hospitals and ambulatory surgery centers: United States, 2010. Natl Health Stat Report. 2017, 102:1-15.

17. Ziembka-Davis M, Nielsen M, Kraus K, Duncan N, Nayyar N, Meneghini RM: Identifiable risk factors to minimize postoperative urinary retention in modern outpatient rapid recovery total. Joint Arthroplasty. J Arthroplasty. 2019, 34:543-547. 10.1016/j.arth.2019.05.015

18. Chung F: Recovery pattern and home-readiness after ambulatory surgery. Anesth Analg. 1995, 80:896-902. 10.1097/00000539-199505000-00008

19. Pavlin DJ, Rapp SE, Polissar NL, Malmgren JA, Koerschgen M, Keyses H: Factors affecting discharge time in adult outpatients. Anesth Analg. 1998, 87:816-826. 10.1097/00000539-199810000-00014

20. Lau H, Brooks DC: Predictive factors for unanticipated admissions after ambulatory laparoscopic cholecystectomy. Arch Surg. 2001, 136:1150-1153. 10.1001/archsurg.136.10.1150

21. Awan FN, Zulkifli MS, McCormack O, Manzoor T, Ravi N, Meibigen B, Reynolds IV: Factors involved in unplanned admissions from general surgical day-care in a modern protected facility. Ir Med J. 2015, 106:153-4.

22. Naguib M: Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007, 104:575-581. 10.1213/01.ane.0000244594.63518.fc

23. Paton F, Pauliden M, Chambers D, et al.: Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation† †The research material on which this article is based is protected by Crown Copyright. Br J Anaesth. 2010, 105:558-567. 10.1093/bja/aeq269